The Scientific Registry of Transplant Recipients (SRTR) is responsible for understandable reporting of program metrics, including transplant rate, waitlist mortality, and posttransplant outcomes. SRTR developed five-tier systems for each metric to improve accessibility for the public. We investigated the associations of the five-tier assignments at listing with all-cause candidate mortality after listing, for candidates 
| INTRODUC TI ON
The Scientific Registry of Transplant Recipients (SRTR) is required to publicly report pretransplant and posttransplant outcomes. 1 Pretransplant outcomes include the transplant rate and waitlist mortality rate. The former is the relative rate of transplants performed at a program compared with the national rate; it is important because transplant typically confers a survival benefit compared with remaining on the waiting list. [2] [3] [4] The latter is the relative rate of mortality after listing but before transplant. Posttransplant outcomes include patient and graft survival 1 year after transplant.
The Centers for Medicare & Medicaid Services (CMS) and the Organ Procurement and Transplantation Network (OPTN) monitor 1-year posttransplant outcomes for regulatory purposes, and SRTR public reporting has traditionally focused on 1-year posttransplant outcomes. Yet, posttransplant outcomes may fail to accurately inform patients regarding expected survival experiences after listing because many patients, especially candidates for kidney and liver transplant, will never undergo transplant. 5, 6 Instead, a program's ability to quickly perform transplants in waitlisted candidates and minimize mortality on the waiting list may be more strongly associated with mortality after listing than posttransplant outcomes. Thus, additional emphasis on transplant rate and waitlist mortality may be justified in the public reporting.
We investigated the relationship of (a) adjusted transplant rate ratios, (b) adjusted waitlist mortality rate ratios, and (c) adjusted 1-year posttransplant graft survival hazard ratios [HRs] at listing with patient mortality after listing. Specifically, after categorizing each metric into five tiers that range from below average to above average, 7 we estimated the HR for one additional tier in each metric on mortality after listing. Categorization of pretransplant and posttransplant metrics into five tiers requires calculation of a continuous score that ranges from 0 (below average) to 1 (above average). To identify potential nonlinearity in these scores, we also estimated the association of the continuous score for each outcome (referred to throughout as the five-tier score) with mortality after listing. Separate analyses were performed for kidney, liver, lung, and heart transplantation to ensure relevance to the broader transplant community.
| MATERIAL S AND ME THODS
This study used SRTR data. The SRTR data system includes data on all donors, waitlisted candidates, and transplant recipients in the United States, submitted by the members of OPTN, and has been described elsewhere. 8 The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight of the activities of the OPTN and SRTR contractors. 
| Evaluated cohort

| Five-tier systems for pretransplant and posttransplant metrics
Pretransplant metrics at listing were the adjusted transplant rate ratios and adjusted waitlist mortality rate ratios included in the PSR at listing. Similarly, the posttransplant metric at listing was the 1-year posttransplant graft survival HR included in the PSR at listing. Bayesian methodology estimated program-specific posterior distributions for each metric. Specifically, because the number of observed events for each metric follows a Poisson distribution, a conjugate gamma prior with shape and rate parameters equal to 2 was used. Thus, the posterior distribution for each metric was a gamma distribution that depended only on the number of observed and expected events and can be calculated with archived PSRs.
9
The five-tier systems for each metric used a two-step process. The first step calculates a rating between 0 and 1 by taking the expectation of a logistic-type utility function with respect to the posterior distribution. The second step assigns the rating to one of the five tiers based on a priori cutoffs. The logistic-type functions were selected to ensure that higher ratings correspond to better outcomes and that the distribution of programs was relatively bell shaped, with most programs in tier 3.
For waitlist mortality and posttransplant graft survival, the logistic-type function had a relatively steep slope that assigned more weight to hazard ratios or waitlist mortality rate ratios below 1. 7 In contrast, the function for transplant rate had a more gradual slope and assigned more weight to hazard ratios above 1. The algorithm for transplant rate was modified because high transplant rate ratios correspond to good rather than poor outcomes, and transplant rate ratios are significantly more variable than waitlist mortality and posttransplant outcomes and required a more gradual slope to ensure a relatively bell-shaped distribution across tiers.
Technical details appear in the Supplementary Materials.
| Statistical analysis
Linear trends estimated the association of tier at listing for the pre- All analyses were completed in R v3.3.3, 10 Cox proportional hazard models were estimated with the "survival" package, 11 and the multiple imputation was completed by the "mice" package. 12 
| RE SULTS
| Kidney transplantation
During the cohort period, 104 063 candidates joined the kidney waiting list (Table 1 and Figure 1 ). At listing, average age was 52 years and dialysis duration was 3 years. The most common blood type was O, and the most common diagnosis was diabetes. Albumin was the most-missing risk factor, at 6.7%; most risk factors were missing less than 0.1%. See Table S1 for a summary of missing data.
Tier assignments at listing for transplant rate and waitlist mortality were associated with mortality after listing. Specifically, an additional tier in the transplant rate evaluation was associated with a 5% lower hazard of mortality after listing (HR, 0.93 0.95 0.97 ), whereas an additional tier in the waitlist mortality evaluation was associated with a 4% lower hazard of mortality after listing (HR, 0.94 0.96 0.99 ).
Approximately two additional tiers in the transplant rate evaluation corresponded to three additional tiers in the waitlist mortality evaluation. In contrast, tier assignment at listing for posttransplant graft survival had no apparent association with mortality after listing for kidney candidates (HR, 0.97 1.00 1.02 ). None of the evaluations had notable nonlinear associations ( Figure S1 ). Thus, transplant rate had the strongest association with mortality after listing in kidney transplantation.
| Liver transplantation
For the 32 815 candidates who joined the liver waiting list (Table 2 and Figure 2 ), average age at listing was 56 years and laboratory model for end-stage liver disease (MELD) score was 18. Most candidates were white with blood type O; 9.6% had hepatocellular carcinoma exceptions at listing. The most-missing risk factors were education status (7.1%) and prior malignancy (3.6%). Most factors were missing less than 0.1%. See Table S2 for a summary of missing data.
The tier assignment for the transplant rate evaluation at listing was strongly associated with mortality after listing for liver candidates; an additional tier was associated with a 10% lower hazard 
| Lung transplantation
Among the 6998 candidates who joined the lung waiting list, average age at listing was 55 years and average lung allocation score was 45 (Table 3 and Figure 3 ). Most candidates were in diagnosis group D.
The most-missing risk factor was central venous pressure, at 11.3%; missingness was between 2.5% and 5.4% for several other measures of lung function, eg, 3.1% for predicted forced expiratory volume. For most other risk factors, missingness was less than 0.1%. See Table S3 for a summary of missing data.
Tier assignment at listing for posttransplant graft survival was associated with mortality after listing for lung candidates; an additional tier in the posttransplant graft survival evaluation was associated with a 6% lower hazard of mortality after listing (HR, 0.90 0.94 0.98 ).
An additional tier in the waitlist mortality evaluation was associated with 3% lower hazard of mortality after listing, although the difference was not significant (HR, 0.93 0.97 1.01 ). Importantly, the transplant rate evaluation had a U-shaped association with mortality after listing; the association decreased until a score of 0.5 and then increased ( Figure S3 ). Thus, lung programs with average transplant rates were associated with lower mortality after listing than lung programs with below-or above-average rates.
| Heart transplantation
Among the 9637 candidates who joined the heart waiting list, average age was 53 years (Table 4 and Figure 4 ) and the most common blood type was O. Common primary diagnoses were cardiomyopathy (55%) and coronary artery disease (35.4%). Level of missingness was nontrivial for many cardiac measurements. For example, missingness was highest for pulmonary wedge pressure, at 11.1%, and was 4.5% for pulmonary systolic blood pressure. However, most risk factors were less than 0.1% missing. See Table S4 for a summary of missing data.
Tier assignment at listing for the transplant rate evaluation was associated with mortality after listing for heart candidates;
an additional tier in the transplant rate evaluation was associated with 4% lower hazard for survival after listing (HR, 0.92 0.96 1.00 ).
The waitlist mortality and posttransplant graft survival evaluations had no apparent association. Transplant rate had a nonlinear association that was relatively constant for programs with belowaverage transplant rates, decreasing for programs with aboveaverage rates ( Figure S4 ).
| D ISCUSS I ON
SRTR is required to publish PSRs that patients and their families can "accurately and efficiently" use and understand. 1 The ability of preand posttransplant metrics reported in the PSRs to predict mortality after listing is a fundamental component of their utility in decision making. Specifically, the relative importance of transplant rate, waitlist mortality, and posttransplant metrics at listing may better inform patients regarding the types of programs that may minimize mortality after listing. For example, in kidney transplantation, both the waitlist mortality and transplant rate metrics were associated with mortality after listing. However, transplant rate had a stronger association, and three additional tiers in waitlist mortality would be required to offset two additional tiers in transplant rate. To aid in patient decision making, these and other program differences should be conveyed to transplant candidates in the public reporting using plain language or graphical descriptions. 13 The most effective approach for communicating to patients and their families the relative importance of different evaluations is not clear. For example, a plain language description could explicitly emphasize the relative importance of transplant rates to mortality after listing in kidney, liver, and heart transplantation, but a graphical illustration of the relative balance may provide better understanding. Further research to test reports with potential users is therefore needed to determine the best approach. 13 For example, patient interviews could provide feedback on the language used, and a randomized trial could assess the effect of different presentations on decision making in the general public. A good approach would help users interpret information by identifying outcomes associated with patient mortality after listing, eg, emphasizing transplant rate over posttransplant graft survival in liver transplantation.
Meanwhile, a reasonable approach is graphical representations with simple numeric and plain language descriptions.
We found that the relative importance of pre-and posttransplant outcomes was organ specific. For example, transplant rate and waitlist mortality were associated with mortality after listing in kidney transplantation, but only posttransplant graft survival was associated with mortality after listing in lung transplantation. The different patterns of association for pre-and posttransplant outcomes suggest that a uniform approach to public reporting across each organ is not feasible. Instead, each organ should be considered separately to ensure that evaluations relevant to patient outcomes are appropriately emphasized. This is a strength, rather than a weakness, given that most patients are interested in transplants of a single organ.
Additional important considerations for public reporting per-
tain to the ability to predict mortality after listing. Specifically, public reporting can incentivize quality improvement efforts across all programs. 14 This phenomenon has historically occurred for posttransplant metrics due to, for example, CMS's regulatory review. at transplant. 16 Further public reporting of transplant rates could reduce program-level variability because some programs could improve transplant rates through modifications to offer acceptance practices. However, as a consequence, the association between transplant rate metrics and mortality after listing may attenuate over time, although, in this hypothetical example, the public reporting of transplant rate metrics would still indirectly benefit candidates through more standardized access to transplant.
These prospective associations with mortality after listing do not reflect the relative differences in evaluations within a PSR cycle.
For example, an additional tier in a liver program's transplant rate was associated with a 10% lower hazard of mortality after listing despite the transplant rate ratios differing by a much larger amount, eg, approximately a 40% increase within a PSR evaluation cohort.
However, none of the outcomes directly measure mortality after listing. Instead, posttransplant graft survival and waitlist mortality measure two separate causes of mortality after listing, whereas transplant rate measures the relative rate at which a program transitions candidates from the pretransplant period with a relatively high mortality risk to the posttransplant period with a relatively low mortality risk; that is, transplant rate measures a concept that is, at best, indirectly related to mortality after listing. In addition, even if the pre-and posttransplant metrics were intended to prospectively predict mortality after listing, the predictive performance of statistical methods is almost always worse than the performance on the data used to determine the metrics. 17 In lung transplantation, the nonlinear association between transplant rate and mortality after listing is surprising because of the general perception that transplant conveys a survival benefit compared with remaining on the waiting list. Yet, the increased mortality after listing for candidates at lung programs with the best transplant rates suggests that aggressive acceptance behavior may not provide a survival benefit in every situation in lung transplantation, eg, acceptance of a high-risk donor for a candidate with relatively low waitlist mortality. 18 A potential cause is the less severe organ shortage in lung transplantation compared with kidney and liver transplantation. 5, 6, 19 A less severe organ shortage may enable lung transplant candidates to decline offers from high-risk donors because of a better probability of subsequently receiving an organ from a better donor. Alternatively, programs with high transplant rates could list candidates with unmeasured risk factors at a higher rate than programs with average transplant rates. However, such a situation could induce an association between transplant rates and posttransplant outcomes or waitlist mortality, but no such associations exist. 20 Regardless, further research should investigate the potential survival benefit of lung transplant with, for example, a low-quality donor organ compared with remaining on the waiting list for a better donor. Figures S5-S8 ). Alternative statistical methods that rely on estimators with fewer assumptions could be considered for, eg, the 3-year probability or restricted mean of mortality after listing.
27,28
The program-specific effect on patient mortality after listing could be a better and more direct approach to public reporting with a limited number of factors. In contrast, the risk adjustment for mortality after listing was based on new waitlist mortality models that include a broad spectrum of risk factors and flexible splines for continuous factors. 20, 29 If the new models identify a program's risk tolerance better than the old models, then the effect of pre-and/or posttransplant metrics could be attenuated.
Pre-and posttransplant evaluations at listing are associated with prospective patient mortality after listing. Although transplant rate was most important in kidney, liver, and heart transplantation, the appropriate balance among transplant rate, waitlist mortality, and posttransplant graft survival was organ-specific. 
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